Find Clinical Trials | Cedars-Sinai

140 results found

Colon

Roche, WO42758, Intrinsic, Ph 1/1b, OL, mCRC, Inavolisib + Cetuximab or Inavolisib + Bevacizumab

Inavo + Cetux Treatment Arm Primary Efficacy Objectives: To evaluate the efficacy of Inavo + Cetux in PIK3CA-mutated CRC with no detected RAS (KRAS, NRAS) or BRAFV600E mutations Secondary Efficacy Objectives: To evaluate the efficacy of Inavo + Cetux ...

Gastrointestinal Cancer, Liver Cancer

Pembrolizumab Plus Lenvatinib in Combination With MK-6482 in Multiple Solid Tumors

The purpose of this study is to evaluate the combined use of the drugs pembrolizumab (pembro), lenvatinib, and belzutifan in people with certain types of solid tumors. Pembro and lenvatinib have been approved by the ...

Brain and Nervous System

Tirabrutinib in Patients With Primary Central Nervous System Lymphoma

The purpose of this study is to evaluate the effects of an investigational drug called tirabrutinib when given alone for the treatment of primary central nervous system lymphoma (PCNSL) in individuals who have already received ...

Prostate

NRG, NRG-GU010, Ph 3, Open Label, Prostate, RT vs. RT + ADT vs. RT + ADT + Darolutamide

1.1 Primary Objectives: 1.1.1 De-Intensification Study: To determine whether men with National Comprehensive Cancer Network (NCCN) unfavorable intermediate risk (UIR) prostate cancer and lower Decipher genomic risk (Decipher score < 0.40) treated with RT alone instead of ...

Breast, Colon, Esophagus, Kidney, Lung, Melanoma, Ovary

Shionogi, 2023P2411(aCCeleR8-001), Ph1b/2,Open,Advanced Solid Tumors,S-531011 +/- Pembrolizumab

Primary: -To evaluate the safety and tolerability of S-531011 and to determine the MTD and/or RP2D of S-531011. Secondary: - To evaluate the preliminary antitumor activity of S-531011 per RECIST version 1.1a. - To characterize the PK profile ...